EP0690727A1 - Hexadentate ligands useful in radiographic imaging agents - Google Patents

Hexadentate ligands useful in radiographic imaging agents

Info

Publication number
EP0690727A1
EP0690727A1 EP94907172A EP94907172A EP0690727A1 EP 0690727 A1 EP0690727 A1 EP 0690727A1 EP 94907172 A EP94907172 A EP 94907172A EP 94907172 A EP94907172 A EP 94907172A EP 0690727 A1 EP0690727 A1 EP 0690727A1
Authority
EP
European Patent Office
Prior art keywords
group
same
different
mono
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94907172A
Other languages
German (de)
French (fr)
Other versions
EP0690727A4 (en
Inventor
William L. Neumann
Raghavan Rajagopalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Publication of EP0690727A1 publication Critical patent/EP0690727A1/en
Publication of EP0690727A4 publication Critical patent/EP0690727A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5027—Polyphosphines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3

Definitions

  • the present invention relates to novel ligands for forming radionuclide complexes, new complexes incorporating such ligands, processes for preparing such complexes, imaging agents incorporating such complexes, and methods of imaging using such imaging agents.
  • radiographic imaging agents for visualizing skeletal structures, organs, or tissues, is well known in the area of biological and medical research and diagnostic procedures.
  • the procedure whereby such imaging is accomplished generally involves the preparation of radioactive agents, which, when introduced to the biological subject, are localized in the specific skeletal structures, organs or tissues to be studied.
  • the localized radioactive agents may then be traced, plotted or scintiphotographed by radiation detectors, such as, traversing scanners or scintillation cameras.
  • the distribution and relative intensity of the detected radioactive agents indicates the position of the tissue in which the agent is localized, and also shows the presence of aberrations, pathological conditions or the like.
  • the radiographic imaging agents comprise radionuclide-labelled compounds; such as complexes of technetium 99m, rhenium 186 or rhenium 188, or other applicable radionuclides; with appropriate carriers, and auxiliary agents, such as delivery vehicles suitable fcr injection into, or aspiration by, the patient, physiological buffers and salts, and the like.
  • the present invention relates particularly to novel preorganized hexadentate ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.
  • novel ligands having the general formula:
  • R x , R 2 and R 3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbarr.oyl; 1 and m may be the same or different and are from 1 to 6; Q and Z may be the same or different and are an 0, N or S atom; X and Y may be the same or different and are selected from the group consisting of -OH R 4 COOH COSH
  • R 4 , R 5 and R 6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, a ino, alkylamino, aminoalkyl, and carba oyl.
  • ligands according to the present invention have the general formula I above, wherein R : is hydrogen; R 2 and R 3 are methyl groups; 1 and are 3; Q and Z are oxygen atoms; and X and Y are the same and are as defined above. In a further preferred embodiment, X and Y are the same and are
  • the novel ligands described above may be incorporated into radionuclide complexes used as radiographic imaging agents.
  • the complexes of the present invention are prepared by reacting one of the aforementioned ligands with a radionuclide containing solution under radionuclide complex forming reaction conditions.
  • a technetium agent is desired, the reaction is carried out with a pertechnetate solution under technetium 99m complex forming reaction conditions.
  • the solvent may then be removed by any appropriate means, such as evaporation.
  • the complexes are then prepared for administration to the patient by dissolution or suspension in a pharmaceutically acceptable vehicle.
  • the ligands of the present invention may be prepared from commercially available starting materials such as 2-nitrobenzylbromide, hydroxyethylethylenedia ine, etc. by standard synthetic methods as described in the following Examples.
  • Radionuclide complexes according to the present invention may have the general formula:
  • M is an appropriate radionuclide such as technetium or rhenium, and wherein R lf R 2 , R 3 , 1, m, X, Y, Q, and Z are as defined above in formula I.
  • the radionuclide containing solution may be obtained from radionuclide generators in a known manner.
  • the pertechnetate solution may be obtained from a technetium generator in a known manner.
  • the radionuclide complex forming reaction is then carried out under appropriate reaction conditions.
  • the technetium 99m complex forming reaction is carried out under technetium complex forming temperatures, e.g. 20° C to 100°C for 10 minutes to several hours.
  • a large excess of the appropriate ligands over the radionuclide complex forming amounts is preferably used.
  • at least a ten fold excess of the ligands over the pertechnetate solution is used.
  • the pertechnetate is used in technetium complex forming amounts, e.g. about IO 6 to IO 12 molar amounts.
  • the present invention also relates to imaging agents containing a radionuclide complex as described above, in an amount sufficient for imaging, together with a pharmaceutically acceptable radiological vehicle.
  • the radiological vehicle should be suitable for injection or aspiration, such as human serum albumin; aqueous buffer solutions, e.g tris (hydromethyl) aminomethane (and its salts) , phosphate, citrate, bicarbonate, etc; sterile water; physiological saline; and balanced ionic solutions containing chloride and or dicarbonate salts or normal blood plasma cations such as Ca *2 , Na * , K * , and Mg *2 .
  • the concentration of the imaging agent according to the present invention in the radiological vehicle should be sufficient to provide satisfactory imaging, for example, when using an aqueous solution, the dosage is about 1.0 to 50 millicuries.
  • the imaging agent should be administered so as to remain in the patient for about 1 to 3 hours, although both longer and shorter time periods are acceptable. Therefore, convenient ampules containing 1 to 10 ml of aqueous solution may be prepared.
  • Imaging may be carried out in the normal manner, for example by injecting a sufficient amount of the imaging composition to provide adequate imaging and then scanning with a suitable machine, such as a gamma camera.
  • the complexes according to the present invention may be prepared in accordance with the examples set forth below.
  • Acetylacetone (1.51 g, 15.1 mmol) was added to a solution of 4,5-diamino-l,8-bis(dephenylphosphoro) -octane (3.40 g, 7.50 mmol) in methanol (20 ml) and the mixture was heated to reflux for 5 minutes, allowed to cool and stirred at ambient temperature for 1 hour. The solvent was removed under reduced pressure and the residue was triturated with hexanes (5 X 50 ml) . The combined hexane extracts were evaporated to yield a viscous oil. This crude material was purified by radial chromatography ( ⁇ i0 2 , 3:1 hexanes - ethylacetate) to furnish the desired ligand as a yellow viscous oil.

Abstract

The present invention relates particularly to novel preorganized hexadentate ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.

Description

HEXADENTATE LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS
This is a continuation-in-part application of United States application serial number 07/627,176 filed December 14, 1990.
Background of the Invention
The present invention relates to novel ligands for forming radionuclide complexes, new complexes incorporating such ligands, processes for preparing such complexes, imaging agents incorporating such complexes, and methods of imaging using such imaging agents.
The use of radiographic imaging agents for visualizing skeletal structures, organs, or tissues, is well known in the area of biological and medical research and diagnostic procedures. The procedure whereby such imaging is accomplished, generally involves the preparation of radioactive agents, which, when introduced to the biological subject, are localized in the specific skeletal structures, organs or tissues to be studied. The localized radioactive agents may then be traced, plotted or scintiphotographed by radiation detectors, such as, traversing scanners or scintillation cameras. The distribution and relative intensity of the detected radioactive agents indicates the position of the tissue in which the agent is localized, and also shows the presence of aberrations, pathological conditions or the like.
In general, the radiographic imaging agents comprise radionuclide-labelled compounds; such as complexes of technetium 99m, rhenium 186 or rhenium 188, or other applicable radionuclides; with appropriate carriers, and auxiliary agents, such as delivery vehicles suitable fcr injection into, or aspiration by, the patient, physiological buffers and salts, and the like.
Detailed Description of the Invention
The present invention relates particularly to novel preorganized hexadentate ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes. In particular the present invention relates to novel ligands having the general formula:
Formula I
wherein Rx, R2 and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbarr.oyl; 1 and m may be the same or different and are from 1 to 6; Q and Z may be the same or different and are an 0, N or S atom; X and Y may be the same or different and are selected from the group consisting of -OH R4 COOH COSH
wherein R4, R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, a ino, alkylamino, aminoalkyl, and carba oyl.
In a preferred embodiment, ligands according to the present invention have the general formula I above, wherein R: is hydrogen; R2 and R3 are methyl groups; 1 and are 3; Q and Z are oxygen atoms; and X and Y are the same and are as defined above. In a further preferred embodiment, X and Y are the same and are
The novel ligands described above, may be incorporated into radionuclide complexes used as radiographic imaging agents. The complexes of the present invention are prepared by reacting one of the aforementioned ligands with a radionuclide containing solution under radionuclide complex forming reaction conditions. In particular, if a technetium agent is desired, the reaction is carried out with a pertechnetate solution under technetium 99m complex forming reaction conditions. The solvent may then be removed by any appropriate means, such as evaporation. The complexes are then prepared for administration to the patient by dissolution or suspension in a pharmaceutically acceptable vehicle.
The ligands of the present invention may be prepared from commercially available starting materials such as 2-nitrobenzylbromide, hydroxyethylethylenedia ine, etc. by standard synthetic methods as described in the following Examples.
Radionuclide complexes according to the present invention may have the general formula:
Formula II
wherein M is an appropriate radionuclide such as technetium or rhenium, and wherein Rlf R2, R3, 1, m, X, Y, Q, and Z are as defined above in formula I. In a preferred embodiment a technetium radionuclide complex having the general formula II may be formed from a pertechnetate solution and a ligand having the general formula I above, wherein Rt is a methyl group, R2 is hydrogen, R3 is a methyl group, l = 3, m = 3, Q = 0, Z = 0, and wherein X and Y are the same and are as defined above.
The radionuclide containing solution may be obtained from radionuclide generators in a known manner. For example, when forming a technetium complex, the pertechnetate solution may be obtained from a technetium generator in a known manner. The radionuclide complex forming reaction is then carried out under appropriate reaction conditions. For example, the technetium 99m complex forming reaction is carried out under technetium complex forming temperatures, e.g. 20° C to 100°C for 10 minutes to several hours. A large excess of the appropriate ligands over the radionuclide complex forming amounts is preferably used. For example, when forming a technetium complex, at least a ten fold excess of the ligands over the pertechnetate solution is used. The pertechnetate is used in technetium complex forming amounts, e.g. about IO6 to IO12 molar amounts.
The present invention also relates to imaging agents containing a radionuclide complex as described above, in an amount sufficient for imaging, together with a pharmaceutically acceptable radiological vehicle. The radiological vehicle should be suitable for injection or aspiration, such as human serum albumin; aqueous buffer solutions, e.g tris (hydromethyl) aminomethane (and its salts) , phosphate, citrate, bicarbonate, etc; sterile water; physiological saline; and balanced ionic solutions containing chloride and or dicarbonate salts or normal blood plasma cations such as Ca*2, Na*, K*, and Mg*2. The concentration of the imaging agent according to the present invention in the radiological vehicle should be sufficient to provide satisfactory imaging, for example, when using an aqueous solution, the dosage is about 1.0 to 50 millicuries. The imaging agent should be administered so as to remain in the patient for about 1 to 3 hours, although both longer and shorter time periods are acceptable. Therefore, convenient ampules containing 1 to 10 ml of aqueous solution may be prepared.
Imaging may be carried out in the normal manner, for example by injecting a sufficient amount of the imaging composition to provide adequate imaging and then scanning with a suitable machine, such as a gamma camera.
The complexes according to the present invention may be prepared in accordance with the examples set forth below.
7 Example 1
Preparation of
Acetylacetone (1.51 g, 15.1 mmol) was added to a solution of 4,5-diamino-l,8-bis(dephenylphosphoro) -octane (3.40 g, 7.50 mmol) in methanol (20 ml) and the mixture was heated to reflux for 5 minutes, allowed to cool and stirred at ambient temperature for 1 hour. The solvent was removed under reduced pressure and the residue was triturated with hexanes (5 X 50 ml) . The combined hexane extracts were evaporated to yield a viscous oil. This crude material was purified by radial chromatography (Ξi02, 3:1 hexanes - ethylacetate) to furnish the desired ligand as a yellow viscous oil.
H- MR (toluene-d8) : 5 11.22 (d,2H), 6.95 - 7.55 (m, 20H) , 4.40 (S, 2H) , 2,10 (m, 2H) , 1.95 - 2.05 (multiple singlets, 12H) , .95 - 2.05 (m, 12H) . nC- MR (toluene-d8) : 5 195.5 (S) , 162.4 (S) , 140.5 (S) , 140.3 (S), 140.2 (S), 134.0 (d) , 133.8 (d) , 133.7 (d) , 133.6 (d), 133.4 (d) , 132.5 (d) , 132.4 (d) , 131.4 (d) , 131.3 (d), 95.9 (d) , 58.5 (d) , 54.8 (d) , 38.3 (-CH2-, JPCCC = 12.3 Hz), 35.0 (-CH2-, JPCCC = 12.3 Hz), 29.0 (q) , 28.6 (-CHj-, JPCC = 12.6 Hz), 28.5 (-CH2-, J?cc = 7.5 Hz), 23.0 (-CH2-P-, JPC = 16.9 Hz), 19.2 (q) . 31P-NMR (toluene-d8) : 5 -18.0. Example 2
Preparation of
4-Methoxysalicylaldehyde (2.43 g, 16.0 mmol) was added to a solution of 4, 5-diamino-l, 8-bis (diphenylphosphine) octane (3.60 g, 7.99 mmol) in methanol (25 ml) and the resulting yellow mixture was heated to reflux for 5 minutes, allowed to cool and stirred for 1 hour at ambient temperature. The solvent was removed under reduced pressure and the yellow residue was triturated with hexanes (3 X 50 ml) to provide 5.77 g (93%) or the ligand as an amorphous yellow solid. 13C-NMR (benzene-d6) : δ 165.6 (d) , 165.5 (S) , 164.6 (S) ,
140.3 (S), 140.2 (S) 140.0 (S), 135.7 (S), 135.0 (d) , 134.8 (d), 134.0 (d) 133.9 (d), 133.8 (d) , 133.7 (d) , 133.6 (d), 133.4 (d) 131.6 (d), 131.5 (d) , 113.2 (d) ,
107.4 (d), 101.8 (d) 73.3 (d), 55.1 (q) , 34.3 (-CH2-, J PCCC = 12.2 Hz), 28.4 (-CH2-, JPCC = 12.7 Hz) , 23.1
(-CH2-P-, JPC = 17.0 Hz) 31 P-NMR (benzene-d6) : δ -17
The foregoing has been a discussion of the preferred embodiments of the present invention, but is not intended to limit the invention in any way. Rather, many modifications, variations and changes in detail may be made within the scope of the present invention.

Claims

What is claimed is:
1. A ligand useful in forming radionuclide complexes, said ligand having the general formula:
wherein Rl t R2 and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbamoyl; 1 and m may be the same or different and are from 2 to 5; Q and Z may be the same or different and are an 0, N or S atom; and X and Y may be the same or different and are selected from the group consisting of
-OH R4 COOH COSH
wherein R,, R5 and ?,6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, amino, alkylamino, aminoalkyl, and carbamoyl.
2. A ligand accroding to claim 1, wherein either Rx and R2, or R2 and R3 together may form a carbocyclic or heterocyclic ring of 5 to 7 members.
3. A ligand according to claim 1, wherein R1 and R3 are methyl groups; R2 is hydrogen; 1 and m are 3; and Q and Z are oxygen atoms.
4. A ligand according to claim 1, wherein Rl and R3 are methyl groups; R2 is hydrogen; 1 and m are 3; Q and Z are
oxygen atoms; and X and Y are p Λ wherein R4 and R5
\
R
are phenyl groups.
5. A ligand according to claim 1, wherein R: is hydrogen; R2 and R3 together form a carbocyclic ring; 1 and m are 3; Q and Z are oxygen atoms; and X and Y are
p wherein R4 and R5 are phenyl groups.
6. A ligand according to claim 5, wherein said carbocyclic ring is methoxybenzene. 11
7. A radionuclide complex having the general formula:
wherein M is a radionuclide; and wherein R:, R2 and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbamoyl; 1 and m may be the same or different and are from 2 to 5; Q and Z may be the same or different and are an 0, N or S atom; X and Y may be the same or different and are selected from the group consisting of
-OH -COOH -COSH
/
-N—C—N i P Λ ' A s
\ \ \
R , < wherein R4 R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, amino, alkylamino, aminoalkyl, and carbamoyl.
8. A complex according to claim 7, wherein either R, and R2, or R2 and R3 together may form a carbocyclic or heterocyclic ring of 5 to 7 members.
9. A complex according to claim 7, wherein M is technetium or rhenium.
10. A complex according to claim 7, wherein Rx is a methyl group, R2 is hydrogen, R3 is a methyl group, 1 = 3, m = 3, Q = 0, Z = 0, and wherein X and Y are the same.
11. A complex according to claim 7, wherein Rx and R3 are methyl groups; R2 is hydrogen; 1 and m are 3; Q and Z are
oxygen atoms; and X and Y are p wherein R4 and R5
\ R5
are phenyl groups.
12. A complex according to claim 7, wherein R: is hydrogen; R2 and R3 together form a carbocyclic ring; 1 and m are 3; Q and Z are oxygen atoms; and X and Y are
p wherein R4 and R5 are phenyl groups .
\ R«
13 . A complex according to claim 12 , wherein said carbocyclic ring is ethoxybenzene .
14. A method of making a radionuclide complex having the general formula:
wherein M is a radionuclide; and wherein R1# R2 and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbamoyl; 1 and may be the same or different and are from 2 to 5; Q and Z may be the same or different and are an O, N or S atom; X and Y may be the same or different and are selected from the group consisting of
-OH -COOH -COSH
S
II / / /
-N—C- -As
I \ \ \ wherein R4, R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, amino, alkylamino, aminoalkyl, and carbamoyl; said method comprising reacting a radionuclide containing solution and a ligand having the general formula:
wherein R1# R2, R3, 1, m, X, Y, Q, and Z are as defined above.
15. A method according to claim 14, wherein either R: and R2, or R2 and R3 together may form a carbocyclic or heterocyclic ring of 5 to 7 members.
16. A method according to claim 14, wherein M is technetium or rhenium, and said radionuclide containing solution is a pertechnetate or perrheneate solution respectively.
17. A radiographic imaging agent comprising a complex having the general formula:
wherein M is a radionuclide; and wherein R R-. and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkcxycarbonyl and carbamoyl; 1 and m may be the same or- different and are from 2 to 5; Q and Z may be the same or different and are an 0, N or S atom; X and Y may be the same or different and are selected from the group consisting of
-OH -COOH -COSH
S
II / / /
—N- -c- -As
\ \ \
R wherein R4, R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, amino, alkylamino, aminoalkyl, and carbamoyl; and a pharmaceutically acceptable radiological vehicle.
18. An imaging agent according to claim 17, wherein either R: and R2, or R2 and R3 together may form a carbocyclic or heterocyclic ring of 5 to 7 members.
19. An imaging agent according to claim 17, wherein M is technetium or rhenium.
20. An imaging agent according to claim 17, wherein said vehicle is suitable for injection or aspiration and is selected from the group consisting of human serum albumin, aqueous buffer solutions, sterile water, physiological saline, and balanced ionic solutions containing chloride salts, dicarbonate salts or blood plasma cations.
21. An imaging agent according to claim 17, wherein the concentration of said complex in said vehicle is from about 1.0 to 50 millicuries.
22. A method of radiographic imaging, comprising injecting a sufficient amount of an imaging agent to provide adequate imaging and then scanning with a suitable scanning machine; said imaging agent comprising a complex having the general formula:
wherein M is a radionuclide; and wherein R:, R2 and R3 are the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or pcly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl and carbamoyl; 1 and m may be the same or different and are from 2 to 5; Q and Z may be the same or different and are an 0, N or S atom; X and Y may be the same or different and are selected from the group consisting of OH R. C00H COSH
S F II / / / / -N—C—N > -As I \ \ \ \ wherein R4, R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, and organic compounds having 2 to 10 carbon atoms selected from the group consisting of alkyl, aryl, hydroxyl, alkoxyl, mono- or poly- hydroxyalkyl, mono- or poly- alkoxyalkyl, alkoxycarbonyl, amino, alkylamino, aminoalkyl, and carbamoyl; and a pharmaceutically acceptable radiological vehicle.
23. A method of imaging according to claim 22, wherein either R: and R2, or R2 and R3 together may form a carbocyclic or heterocyclic ring of 5 to 7 members .
24. A method of imaging according to claim 22, wherein M is technetium or rhenium.
25. A method of imaging according to claim 22, wherein said vehicle is suitable for injection or aspiration and is selected from the group consisting of human serum albumin, aqueous buffer solutions, sterile water, physiological saline, and balanced ionic soluticns containing chloride salts, dicarbonate salts or blood plasma cations.
26. A method of imaging according to claim 22, wherein the concentration of said complex in said vehicle is from about 1.0 to 50 millicuries.
EP94907172A 1993-01-06 1994-01-04 Hexadentate ligands useful in radiographic imaging agents Withdrawn EP0690727A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1132 1987-01-05
US113293A 1993-01-06 1993-01-06
PCT/US1994/000281 WO1994015647A1 (en) 1993-01-06 1994-01-04 Hexadentate ligands useful in radiographic imaging agents

Publications (2)

Publication Number Publication Date
EP0690727A1 true EP0690727A1 (en) 1996-01-10
EP0690727A4 EP0690727A4 (en) 1996-03-06

Family

ID=21694536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94907172A Withdrawn EP0690727A4 (en) 1993-01-06 1994-01-04 Hexadentate ligands useful in radiographic imaging agents

Country Status (4)

Country Link
EP (1) EP0690727A4 (en)
JP (1) JPH08505398A (en)
AU (1) AU6085294A (en)
WO (1) WO1994015647A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338864A (en) * 1992-07-06 1994-08-16 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010466A1 (en) * 1990-12-14 1992-06-25 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048480A (en) * 1959-06-09 1962-08-07 Gulf Research Development Co Aviation turbine fuels
US4795626A (en) * 1985-05-10 1989-01-03 University Of Cincinnati 99m Tc.sup.(III) myocardial imaging agents which are non-reducable in vivo
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
US5112595A (en) * 1990-12-21 1992-05-12 Mallinckrodt Medical, Inc. 99MTC(III) myocardial imaging agents and method of use
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010466A1 (en) * 1990-12-14 1992-06-25 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9415647A1 *

Also Published As

Publication number Publication date
JPH08505398A (en) 1996-06-11
WO1994015647A1 (en) 1994-07-21
AU6085294A (en) 1994-08-15
EP0690727A4 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
US5380515A (en) MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonated ligands
EP0375376A2 (en) Macrocyclic aminophosphonic acid complexes, their preparation, formulations and use
IL99485A (en) Ligands useful in radiographic imaging agents
WO1990000854A1 (en) NOVEL Tc-99m COMPLEXES
AU641072B2 (en) Hexadentate ligands useful in radiographic imaging agents
EP0513000B1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
US5330737A (en) Nitrogen-sulfur ligands as opiate receptor drug mimics
EP0690727A1 (en) Hexadentate ligands useful in radiographic imaging agents
US5338864A (en) Hexadentate ligands useful in radiographic imaging agents
US5908931A (en) Preorganized hexadentate ligands useful in radiographic imaging agents
EP0692977B1 (en) Novel heterocycle based nitrogen-sulfur ligands useful in radiographic imaging agents
US5623077A (en) Imidazole based nitrogen sulfur ligands useful in radiographic imaging agents
WO2021108474A1 (en) Method for extraction and purification of ai18f-labeled hbed conjugates
IL100500A (en) 99n tc (iii) myocardial imaging agents and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR

RHK1 Main classification (correction)

Ipc: C07F 9/50

A4 Supplementary search report drawn up and despatched

Effective date: 19960118

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19960724